SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. NEJM online (dostępny pełen tekst)
The primary outcome occurred in 108 of 1648 patients(6.6%) in the semaglutide group and in 146 of 1649 patients (8.9%) in the placebo
group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95; P<0.001 for non-inferiority) …
NEJM, 16 września 2016